An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis

Condition(s) studied

Study summary

Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.

Eligibility

Primary outcome measure(s)

• Identification and validation of a diagnostic classifier enabling discrimination of chronic liver diseases. — 10 years
  OMICS based analyses on plasma and liver tissue

Trial sites (1)

More University of Copenhagen trials in Denmark